Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead Hepsera Launch: Lamivudine-Resistant Hep B Is First Target

Executive Summary

Gilead's roll-out of Hepsera should be helped by a readily identifiable population of approximately 12,000 hepatitis B patients who are resistant to lamivudine (GlaxoSmithKline's Epivir-HBV)

You may also be interested in...



Gilead Hepsera Clears FDA; Hepatitis B Therapy Will Cost $440 Per Month

Gilead is launching the hepatitis B agent Hepsera (adefovir) at a wholesale acquisition cost of $440 per month

Gilead Adefovir Patients Should Be Monitored Every Four Weeks - FDA Cmte.

Gilead's adefovir dipivoxil patients should be monitored every four to eight weeks following initial dosing, FDA's Antiviral Drug Products Advisory Committee recommended during its Aug. 6 meeting

Gilead Adefovir Approval Awaits "Unequivocal" Evidence Of Efficacy At 60 mg

Gilead has begun enrollment in two placebo-controlled trials of a 60 mg dose of adefovir dipivoxil that could provide sufficient evidence to prompt a reconsideration of the HIV therapy by FDA's Antiviral Drugs Advisory Committee.

Related Content

UsernamePublicRestriction

Register

PS040542

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel